Description
Anti-VEGF-C Antibody, Non-Fucosylated (BioBet-1425ZP) is a human monoclonal IgG antibody against VEGF-C. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Glioma; Prostate Cancer; Solid Tumors
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced VEGF-C antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
vascular endothelial growth factor C
Background
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. The encoded protein promotes angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. The proprotein is further cleaved into a fully processed form that can bind and activate VEGFR-2 and VEGFR-3 receptors.
Alternative Names
VEGFC; vascular endothelial growth factor C; VRP; Flt4-L; LMPH1D; FLT4 ligand DHM; vascular endothelial growth factor-related protein
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with VEGFC include Lymphatic Malformation 4 and Hereditary Lymphedema Id.
Related Pathways
Its related pathways are HIF1Alpha Pathway and Signaling by GPCR.
Function
Growth factors play a role in angiogenesis and endothelial cell growth, stimulate their proliferation and migration, and affect the permeability of blood vessels. It may play a role in the angiogenesis of the vein and lymphatic system during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors.
Post-translational modifications
VEGF-B186 is O-glycosylated.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
VGX-100 is a human antibody that acts against the human vascular endothelial growth factor (VEGF)-C protein. Treatment for cancers, particularly glioblastoma and metastatic colorectal cancers, are the first target indications for VGX-100. Additionally, VGX-100 is developing for a number of other cancer indications, and as an agent to treat front-of the-eye diseases.
Antibody Indication
Glioma; Prostate Cancer; Solid Tumors
